Accéder au contenu
Merck

In vitro Antimicrobial Activity of Acne Drugs Against Skin-Associated Bacteria.

Scientific reports (2019-10-12)
Mark A T Blaskovich, Alysha G Elliott, Angela M Kavanagh, Soumya Ramu, Matthew A Cooper
RÉSUMÉ

Acne is a common skin affliction that involves excess sebum production and modified lipid composition, duct blockage, colonization by bacteria, and inflammation. Acne drugs target one or more of these steps, with antibiotics commonly used to treat the microbial infection for moderate to severe cases. Whilst a number of other acne therapies are purported to possess antimicrobial activity, this has been poorly documented in many cases. We conducted a comparative analysis of the activity of common topical acne drugs against the principal etiological agent associated with acne: the aerotolerant anaerobic Gram-positive organism Propionibacterium acnes (recently renamed as Cutibacterium acnes). We also assessed their impact on other bacteria that could also be affected by topical treatments, including both antibiotic-sensitive and antibiotic-resistant strains, using broth microdilution assay conditions. Drugs designated specifically as antibiotics had the greatest potency, but lost activity against resistant strains. The non-antibiotic acne agents did possess widespread antimicrobial activity, including against resistant strains, but at substantially higher concentrations. Hence, the antimicrobial activity of non-antibiotic acne agents may provide protection against a background of increased drug-resistant bacteria.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Colistine sulfate salt, ≥19,000 IU/mg
Sigma-Aldrich
Oxacillin sodium salt, 815-950 μg/mg (Oxacillin)